[P29] Poster Session 29　Lung Cancer/Thoracic Cancer（ICI efficacy 1）

[P29-4] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression（HOT/NJLCG2001）

^○Yasuo Kitamura¹, Hidenori Mizugaki², Yasuyuki Ikezawa³, Ryo Morita⁴, Kazunari Tateishi⁵, Keiki Yokoo⁶, Toshiyuki Sumi⁷, Hajime Kikuchi⁸, Atsushi Nakamura⁹, Maki Kobayashi¹⁰, Mari Aso¹¹, Nozomu Kimura¹², Fumiaki Yoshiike¹³, Megumi Furuta¹⁴, Hisashi Tanaka¹⁵, Motoki Sekikawa¹⁶, Tsutomu Hachiya¹⁷, Keiichi Nakamura¹⁸, Satoshi Oizumi¹⁹ (1.Department of Respiratory Medicine, Kushiro City General Hospital, 2.Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3.Department of Respiratory Medicine, Oji General Hospital, 4.Department of Respiratory Medicine, Akita-Kousei Medical Center, 5.First Department of Internal Medicine, Shinshu University School of Medicine, 6.Department of Respiratory Medicine, Teine Keijinkai Hospital, 7.Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, 8.Department of Respiratory Medicine, Obihiro-Kousei General Hospital, 9.Department of Pulmonary Medicine, Sendai Kousei Hospital, 10.Department of Respiratory Medicine, Miyagi Cancer Center, 11.Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, 12.Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 13.Department of Respiratory Medicine, Nagano Municipal Hospital, 14.Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, 15.Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, 16.Department of Respiratory Medicine, Steel Memorial Muroran Hospital, 17.Department of Respiratory Medicine, Japanese Red Cross Society Suwa Hospital, 18.Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, 19.Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center)